Recruiting

Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

ClinicalTrials.gov IDNCT07185204
PhaseNA
Enrollment60
SponsorMedical College of Wisconsin
Age18 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Postpartum Preeclampsia

About this study

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Pregnant patients ≥ 36 weeks gestation without major fetal anomalies * Age ≥ 18 years * Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital * At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF * 1 or more high risk factors: * History of preeclampsia * Type 1 or 2 diabetes * Multifetal gestation? * Renal disease * Autoimmune disease * 2 or more moderate risk factors: * Nulliparity * BMI \> 30 * First-degree relative with a history of preeclampsia * African American race * Low socioeconomic status * Age \> 35 years * History of low birthweight or small for gestational age * Previous adverse pregnancy outcome * Interpregnancy interval \> 10 years Exclusion Criteria: * Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Chronic hypertension, according to ACOG guidelines * Known allergy or contraindication to nifedipine * Inability or unwillingness to provide informed consent * Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.